A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.

Trial Details

NCT ID

NCT06830889

Phase

PHASE3

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

BL-M07D1
T-DM1

Locations (sample)

Nanjing, Jiangsu, China|32.06167,118.77778
Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Sign the informed consent form voluntarily and follow the protocol requirements;
Women aged ≥18 years and ≤75 years at the time of written informed consent;
Expected survival time ≥6 months;
Patients with histologically confirmed HER2-positive invasive breast cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →